REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

BACKGROUND: Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to imatinib. Underlying oncogenic mechanisms in KP-wtGIST include overexpression...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Broto, Javier, Valverde, Claudia, Hindi, Nadia, Vincenzi, Bruno, Martinez-Trufero, Javier, Grignani, Giovanni, Italiano, Antoine, Lavernia, Javier, Vallejo, Ana, Tos, Paolo Dei, Le Loarer, Francois, Gonzalez-Campora, Ricardo, Ramos, Rafael, Hernández-Jover, Diana, Gutierrez, Antonio, Serrano, Cesar, Monteagudo, Maria, Letón, Rocio, Robledo, Mercedes, Moura, David S., Martin-Ruiz, Marta, López-Guerrero, Jose A., Cruz, Julia, Fernandez-Serra, Antonio, Blay, Jean-Yves, Fumagalli, Elena, Martinez-Marin, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413507/
https://www.ncbi.nlm.nih.gov/pubmed/37559050
http://dx.doi.org/10.1186/s12943-023-01832-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413507/
https://www.ncbi.nlm.nih.gov/pubmed/37559050
http://dx.doi.org/10.1186/s12943-023-01832-9

Ejemplares similares